Circulation:对单双侧胸廓内动脉移植增加桡动脉移植物的疗效

2017-06-02 xiangting MedSci原创

当用于补充SITA或BITA移植物时,额外的RA与中期主要不良心脏事件的风险降低有关。

使用桡动脉(RA)是否可以改善冠状动脉旁路移植术(CABG)手术的临床疗效尚不清楚。动脉血运重建试验(ART)旨在比较双侧胸廓内动脉(BITA)和单纯左胸廓内动脉(SITA)的生存率。在ART中,一大部分患者(约20%)接受了RA移植,而不是隐静脉移植物(SVG)。这项研究旨在通过对ART的事后分析,探讨使用RA而不是SVG来补充SITA或BITA移植物和结局之间的相关性。

参加ART的患者(n = 3102)根据实际接受的导管(如治疗)进行分类。该分析包括除了SITA或BITA移植物之外,接受RA移植物(RA组,n = 632)或仅SVG(SVG组,n = 2105)的2737名患者。主要终点是5年时心肌梗死,心血管死亡和重复血运重建的组合。使用倾向得分匹配和分层Cox回归来比较这两种策略。

MI、心血管死亡和重复血运重建累积发生率分别为RA组2.3%(95%CI 1.1-3.4),3.5%(95%CI 2.1-5.0)和4.4%(95%CI 2.8-6.0); SVG组的3.4%(95%CI 2.0-4.8),4.0%(95%CI 2.5-5.6)和7.6%(95%CI 5.5-9.7)。与SVG组(13.6%; 95%CI 10.8-16.3)(P = 0.005)相比,RA组复合终点显著降低(8.8%; 95%CI 6.5-11.0)。当RA移植物用于补充SITA和BITA移植物时,存在这种关联(相互作用P = 0.62)。

这项事后ART分析显示,当用于补充SITA或BITA移植物时,额外的RA与中期主要不良心脏事件的风险降低有关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745239, encodeId=77b71e452396c, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Nov 21 17:44:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441096, encodeId=65fa144109659, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522386, encodeId=fb7c152238689, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620694, encodeId=dedb1620694cd, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
    2017-11-21 xuyong535
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745239, encodeId=77b71e452396c, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Nov 21 17:44:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441096, encodeId=65fa144109659, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522386, encodeId=fb7c152238689, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620694, encodeId=dedb1620694cd, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745239, encodeId=77b71e452396c, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Nov 21 17:44:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441096, encodeId=65fa144109659, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522386, encodeId=fb7c152238689, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620694, encodeId=dedb1620694cd, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745239, encodeId=77b71e452396c, content=<a href='/topic/show?id=bdc262694bb' target=_blank style='color:#2F92EE;'>#植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62694, encryptionId=bdc262694bb, topicName=植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5e35527958, createdName=xuyong535, createdTime=Tue Nov 21 17:44:00 CST 2017, time=2017-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1441096, encodeId=65fa144109659, content=<a href='/topic/show?id=81a3623569c' target=_blank style='color:#2F92EE;'>#桡动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62356, encryptionId=81a3623569c, topicName=桡动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ae384789560, createdName=12498aa2m63(暂无昵称), createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1522386, encodeId=fb7c152238689, content=<a href='/topic/show?id=46223e39897' target=_blank style='color:#2F92EE;'>#双侧#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37398, encryptionId=46223e39897, topicName=双侧)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=741b11453403, createdName=wangbingxhy, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620694, encodeId=dedb1620694cd, content=<a href='/topic/show?id=c0c9e520310' target=_blank style='color:#2F92EE;'>#移植物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75203, encryptionId=c0c9e520310, topicName=移植物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=153620156575, createdName=10518100zz, createdTime=Sun Jun 04 00:44:00 CST 2017, time=2017-06-04, status=1, ipAttribution=)]

相关资讯

NEJM:缺血性心肌病患者通过冠状动脉旁路移植术有很好的生存获益

在冠状动脉疾病,心脏衰竭和严重左心室收缩功能不全患者中,与单纯药物治疗相比,将冠状动脉旁路移植术(CABG)加入到指南指导医学治疗方法中的生存获益仍不清楚。从2002年7月至2007年5月,共有1212例射血分数为35%或以下,患有冠状动脉疾病并可以接收CABG的患者被随机分配接受CABG加药物治疗(CABG组,610例)和单纯药物治疗(药物治疗组,602例)。主要结果是任何原因引起的死亡。主要次

2016冠状动脉旁路移植术围术期抗血小板治疗专家共识发布

抗血小板治疗是冠状动脉旁路移植术(CABG)围术期最重要的药物治疗之一,抗血小板药物对于CABG改善患者旁路血管通畅率及降低围术期心梗发生率的积极作用已有广泛共识。近年来大量前瞻性临床试验使人们对抗血板治疗的观念不断变化,新的抗血小板药物层出不穷,各种血小板功能检测的方法逐步应用于临床。在这一背景下我国心脏外科医师对于围术期抗血小板治疗的理念亟待更新。我们全面回顾近年来与抗血小板治疗相关的临床试验

Circulation:非体外循环下冠状动脉旁路移植术也是安全可靠的!!!

从研究者提供的数据来看,OPCAB与CPB有着类似的长期预后,而且从OPCAB转为CPB的转化率也较低;从培训进行OPCAB的初级医生也表明OPCAB是可教并且安全的。该研究结果表明OPCAB可以取得与CPB类似的益处。

AHA科学声明:冠状动脉旁路移植术后二级预防

2月9日,美国心脏学会(AHA)在《循环》(Circulation)杂志上发布了《AHA科学声明:冠状动脉旁路移植术后二级预防》。 AHA科学声明:冠状动脉旁路移植术后二级预防之抗血小板治疗建议、抗栓治疗建议、β受体阻滞剂治疗 先来点击下载文献原文吧: 下载:Secondary Prevention After Coronary Artery Bypass Graft Surgery

NEJM:大隐静脉移植后出现动脉瘤——病例报道

女性患者,78岁,因呼吸短促和疲劳就诊于急诊科。30年前曾接受冠状动脉旁路移植术治疗,存在54包年的吸烟史。

Am Heart J :慢性肾脏疾病&急性肾损伤:对冠状动脉旁路移植术患者死亡率具有协同作用

韩国国立首尔大学医学院Seung Seok Han博士等人研究了慢性肾脏疾病(CKD)和急性肾损伤对于行冠状动脉旁路移植术患者死亡率之间的影响,谈论了两者对于GABG术后死亡率的影响,并不是相互排斥,而是相互协同的,其成果发表在3月份American heart journal期刊上。 背景:行冠状动脉旁路移植术(CABG)患者中,急性肾损伤(AKI)和慢性肾脏病(CKD)都是两个备受重视的